![Medicine / Clinical medicine / Anticonvulsants / Health / GABAA receptor positive allosteric modulators / Sodium channel blockers / Epilepsy / RTT / Epileptic seizure / Lorazepam / Phenytoin / Brivaracetam Medicine / Clinical medicine / Anticonvulsants / Health / GABAA receptor positive allosteric modulators / Sodium channel blockers / Epilepsy / RTT / Epileptic seizure / Lorazepam / Phenytoin / Brivaracetam](https://www.pdfsearch.io/img/416fe327ac69187b5414c18004adb2e0.jpg) Date: 2016-02-29 16:05:30Medicine Clinical medicine Anticonvulsants Health GABAA receptor positive allosteric modulators Sodium channel blockers Epilepsy RTT Epileptic seizure Lorazepam Phenytoin Brivaracetam | | U.S. FDA approves UCB’s new epilepsy treatment, BRIVIACT®, for patients with partial-onset seizures • BRIVIACT® (brivaracetam), a new molecular entity, is indicated as adjunctive therapy in the treatment of partialAdd to Reading ListSource URL: www.ucb-usa.comDownload Document from Source Website File Size: 99,93 KBShare Document on Facebook
|